Is ENTA's Q2 2025 EPS forecast signaling a rebound?

**Enanta Pharmaceuticals' (ENTA) Q2 2025 EPS forecast does not indicate a rebound.** Here's why: 1. **Current Financial Position**: Enanta's latest report period is for Q1 2025, and no EPS forecast for Q2 2025 has been provided. However, the company's financial statements for Q3 2024 show an EPS of ($1.07), which is $0.36 higher than the analyst estimate of ($1.43), and revenue that came in at $18 million, versus the consensus estimate of $17.44 million. This suggests a positive performance, but it does not necessarily signal a rebound. 2. **Strategic Shift**: Enanta has recently announced a strategic shift from virology to immunology. This pivot is part of a broader plan to address unmet needs in type two immune diseases. While this shift could potentially lead to growth, it is too early to determine if it will result in a rebound in Q2 2025. 3. **Analyst Estimates**: Analysts have decreased their Q3 2024 earnings per share estimates for Enanta, which could indicate a more cautious outlook for the near term. However, other analysts have increased their FY2024 earnings per share estimates, suggesting a slightly more optimistic view for the full year. 4. **Cash Position and Future Outlook**: Enanta ended 2024 with a cash position of approximately $217 million, with expectations of a $30 million refund from the IRS. The company's financial runway is projected to last until fiscal year 2028. This financial stability could support future growth initiatives, but it does not guarantee a rebound in Q2 2025. In conclusion, while Enanta's recent financial performance and strategic shift suggest potential for growth, the lack of specific EPS forecast data for Q2 2025 and varying analyst estimates make it difficult to conclude that the company is on track for a rebound in that quarter.